Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study

Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

-CDX-0159 IND accepted; Phase 1 study to start by YE 2019-  -CDX-527 on track for IND filing in 1H 2020-

Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study-  -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity-  -Clinical trial collaboration with Merck announced to evaluate CDX-1140 with KEYTRUDA®-

CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

HAMPTON, N.J., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences.

Celldex Therapeutics Announces Upcoming Data Presentations

HAMPTON, N.J., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder, Executive Vice President and Chief Scientific Officer, will present a corporate overview at the Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:40 a.m. EDT in New York. 

Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?

Why Is Celldex (CLDX) Down 2.3% Since Last Earnings Report?

Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.

Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss

The clinical-stage biotech continued to conserve cash while conducting multiple clinical studies in the second quarter.

Celldex Therapeutics Keeps Up Its Penny-Pinching and Pipeline Progress

Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q2 2019 Results - Earnings Call Transcript

Why Is Celldex (CLDX) Down 29.2% Since Last Earnings Report?

Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.

Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experimental cancer drug glemba.

Celldex Therapeutics Continues to Stretch Out Its Cash and Advance Its Pipeline

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?

The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.

Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling

Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.

Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

News for Celldex Therapeutics Stock (CLDX)